Iron Chelation Therapy in Thalassemia: Clinical Review

Clinical Overview

This narrative review addresses transfusional iron overload in patients with β-thalassemia major and other transfusion-dependent anemias managed in hematology settings. Iron (from repeated packed red cell transfusions; ~200 mg Fe per unit) accumulates in liver, heart, and endocrine organs, driving cardiomyopathy, liver disease, and endocrine failure. The paper evaluates three iron chelators—parenteral deferoxamine, and oral deferiprone and deferasirox—focusing on iron removal (serum ferritin, liver iron concentration, myocardial T2*), cardiac function (left ventricular ejection fraction), survival, and adverse events, including creatinine rise (≈36%), gastrointestinal toxicity (≈26%), and rare agranulocytosis.

Study Setting

The article synthesizes data from hospital-based hematology services treating transfusion-dependent patients, primarily β-thalassemia major, but also sickle cell disease, myelodysplastic syndromes, Diamond-Blackfan anemia, aplastic anemia, and rare anemias. Populations include children (≥2 years) and adults with chronic transfusional iron overload. Exposure consists of long-term packed red cell transfusion (≈0.44–0.49 mg Fe/kg/day) and subsequent iron chelation via deferoxamine, deferiprone, or deferasirox at specified oral or subcutaneous doses over months to >7 years.

Study Design and Methods

Aspect	Details
Design	Narrative clinical review of iron chelation in transfusional iron overload, summarizing randomized trials, prospective cohorts, long-term follow-up studies, and case reports in β-thalassemia and other anemias.
How metals were measured	Total body and organ iron assessed via serum ferritin (µg/L), liver iron concentration (LIC, mg Fe/g dry weight by biopsy or imaging), and cardiac iron by MRI T2*; labile plasma iron (LPI) and non-transferrin-bound iron (NTBI) used in mechanistic work.
How microbes were characterized	No microbiological, microbiome, or pathogen-specific measurements were reported; the review is focused entirely on host iron and organ outcomes.
Primary clinical endpoints and follow-up	Cardiac outcomes (myocardial T2*, left ventricular ejection fraction), hepatic iron load (LIC), survival, endocrine function, and safety (cytopenias, renal and hepatic function, gastrointestinal toxicity), with follow-up ranging from 24 weeks to >7 years; sample sizes extend up to 1744 patients in the EPIC deferasirox study.

Major Findings

Systemic iron burden in chronically transfused patients is tightly linked to myocardial, hepatic, and endocrine injury, and chelation regimens differentially modify this trajectory.

Across the summarized studies, deferoxamine clearly improved survival compared with the pre-chelation era but is limited by burdensome subcutaneous infusions and poor adherence. Oral deferiprone at 75–100 mg/kg/day showed superior myocardial iron removal versus deferoxamine, with 27% versus 13% improvement in T2* (p<0.0023) and a 3.1% versus 0.32% absolute rise in left ventricular ejection fraction at 12 months. Combination deferiprone–deferoxamine further improved myocardial T2*, ferritin, and endothelial function, and has reversed established heart failure in case reports. Deferasirox, dosed 20–40 mg/kg once daily, produced dose-dependent reductions in LIC (up to −8.9 mg Fe/g dry weight) and ferritin (up to −926 µg/L), with long-term trials showing progressive increases in the proportion of patients achieving LIC <7 mg Fe/g and ferritin <1000 µg/L over 5 years and significant improvement or prevention of myocardial siderosis by cardiac T2*.

Findings	Details
Burden of transfusional iron	Annual transfusional iron intake ≈0.44–0.49 mg/kg/day in β-thalassemia major leads, without chelation, to early cardiomyopathy and death before the second decade.
Deferoxamine efficacy and limitations	Subcutaneous deferoxamine 20–60 mg/kg/day over 8–12 h, 5–7 nights/week improves survival but has ≈33% non-compliance due to regimen complexity and local/injection-related toxicities.
Deferiprone and cardiac iron	Oral deferiprone increased myocardial T2* more than deferoxamine (27% vs 13% at 12 months; p<0.0023) and improved left ventricular ejection fraction by 3.1% versus 0.32% (p=0.003), with a higher proportion protected from cardiac siderosis.
Combination deferiprone–deferoxamine	Combined therapy enhanced urinary iron excretion, lowered ferritin, improved myocardial T2* and endothelial function, and has reversed iron-induced heart failure and pancreatic endocrine dysfunction in reported cases.
Deferasirox outcomes and safety	Once-daily deferasirox 20–30 mg/kg achieved negative or neutral iron balance in up to 75% of patients with lower transfusion burden and reduced LIC from 20.1 to 11.8 mg Fe/g dry weight over 2.7 years (p<0.0001), with mild–moderate creatinine rise (36%) and gastrointestinal events (26%) as the most frequent adverse effects.

Mechanistic Interpretation & Microbial Metallomics

Above mentioned findings suggest that the pharmacology and pharmacokinetics of different chelators shape tissue iron distribution, labile iron pools, and downstream organ dysfunction in transfusion-dependent patients.

Concept	Implication
Non-transferrin-bound iron (NTBI) and labile plasma iron (LPI) generate reactive oxygen species	Chelators that continuously suppress LPI, such as once-daily deferasirox with 18–24-hour coverage, may better protect myocardium and liver from iron-driven oxidative injury compared with short half-life regimens.
Molecular size and lipophilicity	Deferiprone’s small, lipophilic structure appears to enhance cardiomyocyte iron removal relative to larger, hydrophilic deferoxamine, rationalizing its myocardial benefits and the synergistic use of combination therapy.
Chelator half-life and dosing frequency	Deferoxamine (≈20-minute half-life) requires prolonged infusions; deferiprone (~3–4 hours) requires thrice-daily dosing; deferasirox (8–16 hours) permits once-daily dosing, improving compliance and maintaining iron control.
Organ-specific iron dynamics	Differential responses of cardiac T2* versus hepatic LIC across regimens suggest organ-specific chelation, supporting tailored combinations to target myocardium, liver, and endocrine pancreas.
Systemic chelation as a strong iron perturbation	The review shows that chelators markedly modulate systemic and organ iron pools; although not assessed here, these regimens represent major, controlled perturbations that future work could exploit to study infection risk and host–microbe iron interactions.

Limitations

The article is a narrative review rather than a systematic meta-analysis, combining heterogeneous studies that differ in transfusion intensity, chelator dosing, follow-up duration, and outcome definitions. Direct head-to-head comparisons between all chelation strategies are not uniformly available, and microbiological or microbiome outcomes are not described. Long-term safety data beyond the reported horizons, particularly for high-dose deferasirox and combination regimens, remain limited within this text.

Future perspectives

Building on the summarized evidence, future work should refine individualized chelation strategies based on transfusional iron intake, baseline LIC, myocardial T2*, and labile plasma iron, using these measurements prospectively to titrate dose and sequence or combine agents. Longer-term pediatric studies are needed to clarify growth, endocrine, renal, and hepatic safety as oral chelators are introduced earlier in life. Carefully designed trials could compare monotherapy versus combination schedules for cardiac rescue, including standardized imaging and endocrine endpoints, while also prospectively tracking infection outcomes to understand how sustained manipulation of NTBI and LPI affects host susceptibility.

Key takeaways for Researchers and Clinicians

This review synthesizes clinical experience with three iron chelators in chronically transfused patients, predominantly β-thalassemia major, treated in hematology centers. Elemental iron from packed red cell transfusions accumulates in liver and heart; deferoxamine, deferiprone, and deferasirox differ in route, half-life, and tissue penetration. Oral deferiprone shows superior myocardial iron removal versus deferoxamine, while once-daily deferasirox provides dose-dependent reductions in liver iron and ferritin and improves or preserves cardiac T2* across diverse transfusion-dependent anemias.

Methodologically, the paper underscores the importance of quantitative iron metrics (LIC in mg Fe/g dry weight, serum ferritin in µg/L, and MRI T2* for myocardial iron) and labile plasma iron when evaluating chelation strategies. For clinicians, the practical “clinical take” is that effective, personalized chelation—often using oral agents, alone or in combination—can substantially reduce cardiac and hepatic iron burden and improve survival, provided adherence and safety monitoring (renal, hepatic, hematologic) are rigorous. Translationally, these regimens offer powerful, controlled perturbations of systemic iron biology that future microbial metallomics studies could leverage to interrogate iron-dependent pathways at the host–microbe interface.

Citation

Cianciulli P. Iron Chelation Therapy in Thalassemia Syndromes. Mediterr J Hematol Infect Dis. 2009. DOI 10.4084/MJHID.2009.034